APDAir Products and Chemicals
Q4 2026
EPS
$3.61
est $3.61-0.0%
Revenue
$3.56B
est $3.34B+6.6%

Management guided fiscal 2027 adjusted EPS to $14.15 to $14.50, growth of 5% to 8%, after cutting capital spending by $1.8 billion and exiting two China coal gasification plants. Revenue came in 6.6% above expectations, with adjusted earnings essentially meeting estimates.

Quarterly EPS — reported vs estimate
Our fiscal 2026 results demonstrate the progress we are making to improve our core industrial gas business, strengthen execution, and allocate capital with discipline. We delivered 12 percent adjusted EPS growth, reduced capital expenditures by $1.8 billion, and expanded our industrial gas project backlog through new business wins.

Menezes is pitching Air Products as a leaner industrial gas operator, with $1.8 billion pulled out of capital spending while earnings still grew. Whether that discipline holds as the project backlog builds is the question for fiscal 2027 guidance.

IPO TERMS REVISED
Rezera Inc.RZRA · Nasdaq
$11–$13 / share$200M raise16,666,667 shares

Rezera sets $11-$13 range for $200 million Nasdaq IPO

Rezera just put a number on its Nasdaq debut: $11 to $13 for 16.67 million shares, a roughly $200 million raise with Jefferies, TD Cowen, Cantor and Wedbush PacGrow running the book. Pricing is the next step, and the range is the only shot investors get to gauge the deal before it trades.

Source: SEC filing

Sponsored

CICigna
Q3 2026
EPS
$7.98
est $7.51+6.3%
Revenue
$73.68B
est $72.45B+1.7%

Cigna lifted its full-year adjusted earnings floor to at least $30.60 a share, its fifth straight quarter topping consensus. Pharmacy Benefit Services pre-tax adjusted income fell on large client contract renewals, and management is spending $3 billion on a multi-year modernization push.

Quarterly EPS — reported vs estimate

Sponsored